Posted by Michael Wonder on 06 Apr 2023
Trastuzumab deruxtecan for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment
6 April 2023 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment of adults with HER2 positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen.
This is because Daiichi Sankyo did not provide an evidence submission.
